As problems with the overuse of radical prostate cancer (PCa) treatment are increasingly exposed, focal therapy represents the direction of low- or intermediate-risk PCa management in the future.

However, inaccurate diagnosis and low controllability of focal therapy hinders its clinical translation. In this study, we develop simple structural cyclic arginine-glycine-aspartic (cRGD) peptide-modified and indocyanine green (ICG)-loaded microbubbles (cRGD-ICG-MBs) for ultrasound-photoacoustic imaging and multi-synergistic photothermal therapy (PTT) to address the above problems. Precise PCa diagnosis is achieved by molecular ultrasound imaging. cRGD-targeting and lowfrequency ultrasound with an amplitude of 500 kPa convert MBs into nanoparticles for enhanced ICG delivery. A low-frequency 2500-kPa amplitude ultrasound enables temporary vasculature destruction, which minimizes heat loss during PTT. Specifically, ICG in the tumor region is 14-fold higher than the control, resulting in satisfactory PTT. Our study highlights that this theranostic strategy possesses considerable clinical translational potential, especially in mini-invasive and individualized PCa therapy.

随着过度使用根治性前列腺癌（PCa）治疗的问题日益暴露，局灶性治疗代表了未来中低风险PCa管理的方向。

但是，局灶性治疗的不正确诊断和低可控性阻碍了其临床翻译。在这项研究中，我们开发了用于超声光声成像和多协同光热疗法（PTT）的简单结构的循环精氨酸-甘氨酸-天冬氨酸（cRGD）肽修饰的和吲哚菁绿（ICG）加载的微泡（cRGD-ICG-MBs）。解决以上问题。精确的PCa诊断通过分子超声成像实现。cRGD靶向和振幅为500 kPa的低频超声将MBs转换为纳米颗粒，以增强ICG的递送。低频2500 kPa振幅超声可以暂时破坏脉管系统，从而最大程度地减少PTT期间的热损失。具体而言，肿瘤区域中的ICG比对照高14倍，从而获得令人满意的PTT。